Endometrial Carcinoma Clinical Trials in Houston, Texas
12 recruitingHouston, Texas
Showing 1–12 of 12 trials
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled475 locationsNCT05564377
Recruiting
Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+17 more
Parabilis Medicines, Inc.575 enrolled23 locationsNCT05919264
Recruiting
Phase 1
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Breast CancerColorectal, CancerOvarian Cancer+3 more
Fate Therapeutics113 enrolled3 locationsNCT07216105
Recruiting
Phase 1
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Non-small Cell Lung CancerSolid Tumor, AdultCutaneous Melanoma+4 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430